Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina Faso - Trial NCT05946642
Access comprehensive clinical trial information for NCT05946642 through Pure Global AI's free database. This Phase 3 trial is sponsored by Malaria Consortium and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 13000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Malaria Consortium
Timeline & Enrollment
Phase 3
Jul 15, 2023
Dec 31, 2024
Primary Outcome
Prevalence of symptomatic malaria in children of the target age group by microscopy and molecular methods.
Summary
This will be an open label cluster randomized study with two active intervention and one
 control arm. A cluster will be defined as a selected village. One district implementing
 seasonal malaria chemoprevention (SMC) will be selected, and six villages will be randomly
 selected in this district. These six villages will be randomly allocated to each of the three
 study arms; 1) Arm 1 will receive IPTsc with sulphadoxine-pyrimethamine plus amodiaquine
 (SPAQ); and 2) Arm 2 will receive dihydroartemisinin-piperaquine (DP) plus Ivermectin (IVM),
 all given monthly during the transmission season and 3) Control Arm which will have standard
 malaria control measures including case management and vector control measures as applicable.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05946642
Non-Device Trial